Buscar

 » Publicaciones Recientes

Publicaciones Recientes

Impact of Human Papillomavirus (HPV) 16 and 18 Vaccination on Prevalent Infections and Rates of Cervical Lesions After Excisional Treatment.
Hildesheim A, Gonzalez P, Kreimer AR, Wacholder S, Schussler J, Rodriguez AC, Porras C, Schiffman M, Sidawy M, Schiller JT, Lowy DR, Herrero R; Costa Rica HPV Vaccine Trial (CVT) Group; Costa Rica HPV Vaccine Trial CVT Group. Am J Obstet Gynecol. 2016 Feb 15. pii: S0002-9378(16)00309-4. doi: 10.1016/j.ajog.2016.02.021.

Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections.
Harari A, Chen Z, Rodríguez AC, Hildesheim A, Porras C, Herrero R, Wacholder S, Panagiotou OA, Befano B, Burk RD, Schiffman M; Costa Rica HPV Vaccine Trial Group; Costa Rica HPV Vaccine Trial CVT group. J Infect Dis. 2015 Oct 30. pii: jiv519.

Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.
Beachler DC, Kreimer AR, Schiffman M, Herrero R, Wacholder S, Rodriguez AC, Lowy DR, Porras C, Schiller JT, Quint W, Jimenez S, Safaeian M, Struijk L, Schussler J, Hildesheim A, Gonzalez P; Costa Rica HPV Vaccine Trial (CVT) Group. J Natl Cancer Inst. 2015 Oct 14;108(1). pii: djv302. doi: 10.1093/jnci/djv302. Print 2016 Jan.

Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial.
Panagiotou OA, Befano BL, Gonzalez P, Rodríguez AC, Herrero R, Schiller JT, Kreimer AR, Schiffman M, Hildesheim A, Wilcox AJ, Wacholder S; Costa Rica HPV Vaccine Trial (CVT) Group (see end of manuscript for full list of investigators). BMJ. 2015 Sep 7;351:h4358. doi: 10.1136/bmj.h4358.

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials.
Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, Garland SM, Herrero R, David MP, Wheeler CM; Costa Rica Vaccine Trial and PATRICIA study groups. Lancet Oncol. 2015 Jul;16(7):775-86. doi: 10.1016/S1470-2045(15)00047-9. Epub 2015 Jun 9.

Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica.
Gonzalez P, Hildesheim A, Herrero R, Katki H, Wacholder S, Porras C, Safaeian M, Jimenez S, Darragh TM, Cortes B, Befano B, Schiffman M, Carvajal L, Palefsky J, Schiller J, Ocampo R, Schussler J, Lowy D, Guillen D, Stoler MH, Quint W, Morales J, Avila C, Rodriguez AC, Kreimer AR; Costa Rica HPV Vaccine Trial (CVT) Group. Vaccine. 2015 Apr 27;33(18):2141-51. doi: 10.1016/j.vaccine.2015.03.015. Epub 2015 Mar 18

Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.
Robbins HA, Waterboer T, Porras C, Kemp TJ, Pawlita M, Rodriguez AC, Wacholder S, Gonzalez P, Schiller JT, Lowy DR, Esser M, Matys K, Poncelet S, Herrero R, Hildesheim A, Pinto LA, Safaeian M. Hum Vaccin Immunother. 2014;10(10):2965-74. doi: 10.4161/21645515.2014.972811.

Performance of self-collected cervical samples in screening for future precancer using human papillomavirus DNA testing.
Porras C, Hildesheim A, González P, Schiffman M, Rodríguez AC, Wacholder S, Jiménez S, Quint W, Guillen D, Kreimer AR, Herrero R; CVT Vaccine Group. J Natl Cancer Inst. 2014 Dec 5;107(1):400. doi: 10.1093/jnci/dju400. Print 2015 Jan.

Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates.
Lang Kuhs KA, Porras C, Schiller JT, Rodriguez AC, Schiffman M, Gonzalez P, Wacholder S, Ghosh A, Li Y, Lowy DR, Kreimer AR, Poncelet S, Schussler J, Quint W, van Doorn LJ, Sherman ME, Sidawy M, Herrero R, Hildesheim A, Safaeian M; Costa Rica Vaccine Trial Group.
Am J Epidemiol. 2014 Sep 15;180(6):599-607. doi: 10.1093/aje/kwu168. Epub 2014 Aug 19.

Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial.
Hildesheim A, Wacholder S, Catteau G, Struyf F, Dubin G, Herrero R; CVT Group.
Vaccine. 2014 Sep 3;32(39):5087-97. doi: 10.1016/j.vaccine.2014.06.038. Epub 2014 Jul 10.

Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial.
Lang Kuhs KA, Gonzalez P, Rodriguez AC, van Doorn LJ, Schiffman M, Struijk L, Chen S, Quint W, Lowy DR, Porras C, DelVecchio C, Jimenez S, Safaeian M, Schiller JT, Wacholder S, Herrero R, Hildesheim A, Kreimer AR; Costa Rica Vaccine Trial Group.J Infect Dis. 2014 Dec 15;210(12):1890-9. doi: 10.1093/infdis/jiu357. Epub 2014 Jun 23.

Comparison of antibody responses to human papillomavirus vaccination as measured by three assays.
Robbins HA, Kemp TJ, Porras C, Rodriguez AC, Schiffman M, Wacholder S, Gonzalez P, Schiller J, Lowy D, Poncelet S, Esser M, Matys K, Hildesheim A, Pinto LA, Herrero R, Safaeian M.
Front Oncol. 2014 Jan 13;3:328. doi: 10.3389/fonc.2013.00328. eCollection 2014 Jan 13.

Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial.
Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, Lowy DR, Wacholder S, Schiffman M, Rodriguez AC, Herrero R, Kemp T, Shelton G, Quint W, van Doorn LJ, Hildesheim A, Pinto LA; CVT Group. Cancer Prev Res (Phila). 2013 Nov;6(11):1242-50. doi: 10.1158/1940-6207.CAPR-13-0203

Prevalence of and risk factors for oral human papillomavirus among young women in Costa Rica.
Lang Kuhs KA, Gonzalez P, Struijk L, Castro F, Hildesheim A, van Doorn LJ, Rodriguez AC, Schiffman M, Quint W, Lowy DR, Porras C, Delvecchio C, Katki HA, Jimenez S, Safaeian M, Schiller J, Solomon D, Wacholder S, Herrero R, Kreimer AR; Costa Rica Vaccine Trial Group.
J Infect Dis. 2013 Nov 15;208(10):1643-52. doi: 10.1093/infdis/jit369. Epub 2013 Sep 6.

Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica.
Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jimenez S, Schiller JT, Lowy DR, van Doorn LJ, Wacholder S, Kreimer AR; CVT Vaccine Group. PLoS One. 2013 Jul 17;8(7):e68329. doi: 10.1371/journal.pone.0068329. Print 2013.

Impact of human papillomavirus vaccination on cervical cytology screening, colposcopy, and treatment.
Rodríguez AC, Solomon D, Herrero R, Hildesheim A, González P, Wacholder S, Porras C, Jiménez S, Schiffman M; CVT Group. Am J Epidemiol. 2013 Sep 1;178(5):752-60. doi: 10.1093/aje/kwt047. Epub 2013 Jul 10.

A prospective study of absolute risk and determinants of human papillomavirus incidence among young women in Costa Rica.
Clarke M, Schiffman M, Wacholder S, Rodriguez AC, Hildesheim A, Quint W; Costa Rican Vaccine Trial Group. BMC Infect Dis. 2013 Jul 8;13:308. doi: 10.1186/1471-2334-13-308.

Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial.
Safaeian M, Kemp TJ, Pan DY, Porras C, Rodriguez AC, Schiffman M, Cortes B, Katki H, Wacholder S, Schiller JT, Gonzalez P, Penrose K, Lowy DR, Quint W, van Doorn LJ, Herrero R, Hildesheim A, Pinto LA. Hum Vaccin Immunother. 2013 Jul;9(7):1399-406. doi: 10.4161/hv.24340. Epub 2013 Apr 9.

HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays.
Lin SW, Ghosh A, Porras C, Markt SC, Rodriguez AC, Schiffman M, Wacholder S, Kemp TJ, Pinto LA, Gonzalez P, Wentzensen N, Esser MT, Matys K, Meuree A, Quint W, van Doorn LJ, Herrero R, Hildesheim A, Safaeian M; Costa Rican Vaccine Trial Group. PLoS One. 2013;8(1):e53067. doi: 10.1371/journal.pone.0053067. Epub 2013 Jan 2.

Evaluation of the FTA carrier device for human papillomavirus testing in developing countries.
Gonzalez P, Cortes B, Quint W, Kreimer AR, Porras C, Rodríguez AC, Jimenez S, Herrero R, Struijk L, Hildesheim A, Melchers W. J Clin Microbiol. 2012 Dec;50(12):3870-6. doi: 10.1128/JCM.01698-12. Epub 2012 Sep 19.

Prevalence of and risk factors for anal human papillomavirus infection among young healthy women in Costa Rica.
Castro FA, Quint W, Gonzalez P, Katki HA, Herrero R, van Doorn LJ, Schiffman M, Struijk L, Rodriguez AC, DelVecchio C, Lowy DR, Porras C, Jimenez S, Schiller J, Solomon D, Wacholder S, Hildesheim A, Kreimer AR; Costa Rica Vaccine Trial Group. J Infect Dis. 2012 Oct 1;206(7):1103-10. Epub 2012 Jul 30.

Direct comparison of HPV16 serological assays used to define HPV-naïve women in HPV vaccine trials.
Safaeian M, Ghosh A, Porras C, Lin SW, Rodriguez AC, Schiffman M, Wacholder S, Kemp T, Gonzalez P, Wentzensen N, Esser M, Meuree A, Matys K, Quint W, van Doorn LJ, Sherman ME,Herrero R, Pinto LA, Hildesheim A. Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1547-54. doi: 10.1158/1055-9965.EPI-12-0558. Epub 2012 Jul 2.

Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica.
Herrero R, Wacholder S, Rodríguez AC, Solomon D, González P, Kreimer AR, Porras C, Schussler J, Jiménez S, Sherman ME, Quint W, Schiller JT, Lowy DR, Schiffman M, Hildesheim A; Costa Rica Vaccine Trial Group. Cancer Discov. 2011 Oct;1(5):408-19. doi: 10.1158/2159-8290.CD-11-0131. Epub 2011 Sep 9.

Single nucleotide polymorphisms in the PRDX3 and RPS19 and risk of HPV persistence and cervical precancer/cancer.
Safaeian M, Hildesheim A, Gonzalez P, Yu K, Porras C, Li Q, Rodriguez AC, Sherman ME, Schiffman M, Wacholder S, Burk R, Herrero R, Burdette L, Chanock SJ, Wang SS.

Low risk of type-specific carcinogenic HPV re-appearance with subsequent cervical intraepithelial neoplasia grade 2/3.
Rodríguez AC, Schiffman M, Herrero R, Hildesheim A, Bratti C, Sherman ME, Solomon D, Guillén D, Alfaro M, Morales J, Hutchinson M, Cheung L, Wacholder S, Burk RD.
Int J Cancer. 2012 Oct 15;131(8):1874-81. doi: 10.1002/ijc.27418. Epub 2012 Feb 28.

Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure.
Coseo SE, Porras C, Dodd LE, Hildesheim A, Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Gonzalez P, Sherman ME, Jimenez S, Solomon D, Bougelet C, van Doorn LJ, Quint W, Safaeian M; Costa Rica HPV Vaccine Trial (CVT) Group.
Sex Transm Dis. 2011 Oct;38(10):976-82. doi: 10.1097/OLQ.0b013e31822545c0.

Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine.
Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, González P, Solomon D, Jiménez S, Schiller JT, Lowy DR, Quint W, Sherman ME, Schussler J, Wacholder S; CVT Vaccine Group. J Natl Cancer Inst. 2011 Oct 5;103(19):1444-51. doi: 10.1093/jnci/djr319. Epub 2011 Sep 9.

Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial.
Kreimer AR, González P, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jiménez S, Schiller JT, Lowy DR, van Doorn LJ, Struijk L, Quint W, Chen S, Wacholder S, Hildesheim A, Herrero R; CVT Vaccine Group. Lancet Oncol. 2011 Sep;12(9):862-70. doi: 10.1016/S1470-2045(11)70213-3. Epub 2011 Aug 22. Erratum in: Lancet Oncol. 2011 Nov;12(12):1096.

A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study.
Wentzensen N, Rodriguez AC, Viscidi R, Herrero R, Hildesheim A, Ghosh A, Morales J, Wacholder S, Guillen D, Alfaro M, Safaeian M, Burk RD, Schiffman M.

Switch from cytology-based to human papillomavirus test-based cervical screening: implications for colposcopy.
Porras C, Wentzensen N, Rodríguez AC, Morales J, Burk RD, Alfaro M, Hutchinson M, Herrero R, Hildesheim A, Sherman ME, Wacholder S, Solomon D, Schiffman M.
Int J Cancer. 2012 Apr 15;130(8):1879-87. doi: 10.1002/ijc.26194. Epub 2011 Aug 2.

Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease.
Chaturvedi AK, Katki HA, Hildesheim A, Rodríguez AC, Quint W, Schiffman M, Van Doorn LJ, Porras C, Wacholder S, Gonzalez P, Sherman ME, Herrero R; CVT Group. J Infect Dis. 2011 Apr 1;203(7):910-20. doi: 10.1093/infdis/jiq139.

Long-term persistence of prevalently detected human papillomavirus infections in the absence of detectable cervical precancer and cancer.
Castle PE, Rodríguez AC, Burk RD, Herrero R, Wacholder S, Hildesheim A, Morales J, Rydzak G, Schiffman M; Proyecto Epidemiológico Guanacaste Group. J Infect Dis. 2011 Mar 15;203(6):814-22. doi: 10.1093/infdis/jiq116.